Sign in to Administration. The default account is administrator with blank password.
Home News & Events Latest News Health Products Regulatory Authority drug safety newsletter

Health Products Regulatory Authority drug safety newsletter

Home News & Events Latest News Health Products Regulatory Authority drug safety newsletter
December 19, 2016

The 78th edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support safe and appropriate use of the following medicines: 

  • Otezla (apremilast) – Important advice regarding suicidal ideation and behaviour

  • Lenalidomide (Revlimid) – Advice regarding viral reactivation 

  • Levetiracetam 100mg/ml oral solution – Global reports of medication errors resulting in the administration of higher than intended doses

  • Improved access to educational materials on the HPRA website

  • Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter

The 78th edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support safe and appropriate use of the following medicines: 

  • Otezla (apremilast) – Important advice regarding suicidal ideation and behaviour

  • Lenalidomide (Revlimid) – Advice regarding viral reactivation 

  • Levetiracetam 100mg/ml oral solution – Global reports of medication errors resulting in the administration of higher than intended doses

  • Improved access to educational materials on the HPRA website

  • Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter

Subscribe to our eZine

Receive our monthly newsletter with news and other content relevant to the Irish nursing and midwifery professions.